Search

Your search keyword '"Nurtec (Medication)"' showing total 5 results
Start Over Descriptor "Nurtec (Medication)" Journal globenewswire
5 results on '"Nurtec (Medication)"'

1. Royalty Pharma Reports Third Quarter 2022 Results

Subjects
United States. Food and Drug Administration, Merck & Company Inc. -- Company sales and earnings, Johnson & Johnson -- Company sales and earnings, Pfizer Inc. -- Company sales and earnings, Pharmaceutical industry -- Company sales and earnings, Company earnings/profit, Banking, finance and accounting industries, Business, Xtandi (Medication), Imbruvica (Medication), Cabometyx (Medication), Nurtec (Medication), Januvia (Medication), Trodelvy (Medication), Janumet (Medication)
Abstract

Net cash provided by operating activities (GAAP) of $539 million and Adjusted Cash Receipts[sup.(] [sup.1)] (non-GAAP) of $597 million Announced transactions of up to $3.0 billion year-to-date, including $1.7 billion [...]

Published
2022

2. Royalty Pharma Reports Second Quarter 2021 Results

Subjects
United States. Food and Drug Administration, MorphoSys AG -- Securities, Biotechnology industry -- Securities, Company securities, Banking, finance and accounting industries, Business, Tysabri (Medication), Cabometyx (Medication), Nurtec (Medication), Trodelvy (Medication)
Abstract

NEW YORK, Aug 11, 2021 (GLOBE NEWSWIRE via COMTEX) -- -- Strong growth in net cash provided by operating activities (GAAP) and Adjusted Cash Flow -- Announced transactions of up [...]

Published
2021

3. Royalty Pharma Reports First Quarter 2021 Results

Subjects
United States. Food and Drug Administration, MSCI Inc., Online information services, Online services, Information services, Online information service, Banking, finance and accounting industries, Business, European Union. European Commission, Tysabri (Medication), Xtandi (Medication), Imbruvica (Medication), Cabometyx (Medication), Nurtec (Medication), Trodelvy (Medication)
Abstract

NEW YORK, May 11, May 11, 2021 (GLOBE NEWSWIRE via COMTEX) -- -- Increased Adjusted Cash Receipts guidance for 2021 Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for [...]

Published
2021

4. Royalty Pharma Reports Third Quarter 2020 Results

Subjects
Immunomedics Inc. -- Company sales and earnings, Company earnings/profit, Banking, finance and accounting industries, Business, Imbruvica (Medication), Nurtec (Medication), Trodelvy (Medication)
Abstract

NEW YORK, Nov 10, 2020 (GLOBE NEWSWIRE via COMTEX) -- -- Double-digit growth in Net cash provided by operating activities (GAAP) and Adjusted Cash Receipts -- Increased 2020 guidance: Adjusted [...]

Published
2020

5. Royalty Pharma Reports Second Quarter 2020 Results

Subjects
United States. Food and Drug Administration, Pfizer Inc. -- Company sales and earnings, Pharmaceutical industry -- Company sales and earnings, Company earnings/profit, Banking, finance and accounting industries, Business, Imbruvica (Medication), Nurtec (Medication)
Abstract

NEW YORK, Aug 12, 2020 (GLOBE NEWSWIRE via COMTEX) -- -- Strong double-digit growth in Net cash provided by operating activities (GAAP) and Adjusted Cash Receipts (non-GAAP) -- Company introduces [...]

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results